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Genetics plays an important role in determining pe-
ripheral arterial disease (PAD) pathology, which
causes a spectrum of clinical disorders that range
from clinically silent reductions in blood flow to
limb-threatening ischemia. The cell-type specificity of
PAD pathology, however, has received little attention.
To determine whether strain-dependent differences
in skeletal muscle cells might account for the differ-
ential responses to ischemia observed in C57BL/6 and
BALB/c mice, endothelial and skeletal muscle cells
were subjected to hypoxia and nutrient deprivation
(HND) in vitro, to mimic ischemia. Muscle cells were
more susceptible to HND than were endothelial cells.
In vivo, C57BL/6 and BALB/c mice displayed strain-
specific differences in myofiber responses after
hindlimb ischemia, with significantly greater myofi-
ber atrophy, greater apoptosis, and attenuated myo-
genic regulatory gene expression and stress-respon-
sive signaling in BALB/c mice. Strain-specific deficits
were recapitulated in vitro in primary muscle cells
from both strains after HND. Muscle cells from
BALB/c mice congenic for the C57BL/6 Lsq-1 quanti-
tative trait locus were protected from HND-induced
atrophy, and gene expression of vascular growth fac-
tors and their receptors was significantly greater in
C57BL/6 primary muscle cells. Our results indicate
that the previously identified specific genetic locus
regulating strain-dependent collateral vessel density
has a nonvascular or muscle cell-autonomous role in-
volving both themyogenic program and traditional vas-
2156cular growth factor receptor expression. (Am J Pathol
2012, 180:2156–2169; DOI: 10.1016/j.ajpath.2012.01.032)
Peripheral arterial disease (PAD) results from athero-
sclerosis of peripheral arteries, most commonly in the
lower extremities, and causes a spectrum of clinical
disorders that range from clinically silent reductions in
blood flow to limb-threatening ischemia for which am-
putation is often required.1 In patients with intermittent
claudication, arterial occlusive disease results in re-
duced blood flow manifested as pain with exertion,
whereas in patients with critical limb ischemia (CLI) the
blood flow is inadequate to meet the resting demands
of the limb and results in pain at rest and/or tissue
necrosis. Although less common than claudication, CLI
results in significantly higher morbidity and mortality;
patients with CLI have a risk of major amputation or
death that approaches 40% in 1 year.2–4 Although it
was long held that CLI represents the natural progres-
sive deterioration of PAD in patients with claudication,
this appears not to be the case. In fact, only a small
percentage of patients with claudication eventually de-
velop symptoms of CLI, and a substantial number of
patients with CLI deny prior symptoms of claudication.5
Furthermore, patients with the same degree of lower ex-
tremity athero-occlusive disease can present with either
intermittent claudication or CLI. For these reasons, it ap-
pears that intermittent claudication and CLI represent dis-
tinct phenotypic manifestations of the same underlying ath-
erosclerotic disease process, likely because of differences
in genetic susceptibility. Thus, identifying the genetic mod-
ifiers that predispose individuals to develop CLI remains an
important area of investigation in PAD.
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with which to investigate the mechanisms regulating the
ischemic response.6,7 It is well established that different
inbred strains of mice display markedly different re-
sponses to surgically induced hindlimb ischemia
(HLI).8–10 In particular, the C57BL/6 (BL6) and BALB/c
strains have frequently been compared because of their
markedly different responses to ischemia: BL6 mice dis-
play significantly better collateral artery formation and
limb perfusion and less tissue damage than BALB/c mice
after HLI.10 Nonetheless, little is known about the genetic
mechanisms responsible for these differences in pheno-
type. Chalothorn et al8 demonstrated significantly lower
expression of vascular endothelial growth factor A
(VEGF-A) in response to HLI in BALB/c mice compared
with BL6, suggesting that insufficient angiogenesis or
collateralization is responsible for the poor recovery of
BALB/c mice. In that study, a bioinformatics approach
was used to identify a putative expression quantitative
trait locus (QTL) for VEGF-A expression on mouse chro-
mosome 17, suggesting a polymorphism in BALB/c mice
that may be responsible for reduced VEGF-A expression.
To investigate the genetic mechanisms responsible for
the ischemic response in more detail, our group recently
performed genome-wide scanning with polymorphic
markers in BL6BALB/c offspring.9 A QTL linked to per-
fusion recovery and limb necrosis was identified on chro-
mosome 7 (Lsq-1) with an extremely high degree of statis-
tical significance [logarithm of the odds (LOD) score 7.9].
Using haplotype mapping in BL6, BALB/c, and A/J mice,
in which the ischemic response is similar to that of
BALB/c, this QTL was narrowed to a region encompass-
ing 37 genes. The same locus was subsequently linked to
the regulation of pial collateral vessel number and limita-
tion of cerebral infarct size after middle cerebral artery
occlusion.11,12 Notably, however, none of the candidate
genes in this QTL has a previously defined role in vas-
cular growth, suggesting an as yet undiscovered vascu-
lar function for at least one of these genes, and/or that
genetic influences on other cellular processes play an
important role in the response to ischemia.
Numerous studies of the effects of ischemia on muscle
tissue have centered on vascular cell responses or col-
lateral vessel density, perhaps in part because targeting
the vasculature through therapeutic angiogenesis holds
promise as a potential treatment for ischemic diseases
such as PAD.13 Although studies have examined the
effects of ischemia on other aspects of the limb muscle
response, including mitochondrial biogenesis and the
transition of muscle fibers to more ischemia-tolerant phe-
notypes,14–16 little is known about genetic modifiers of
the skeletal muscle cell response to ischemia. Further-
more, it is unclear whether vascular cells or muscle cells
are more susceptible to ischemia-induced injury. In the
present study, we used both in vitro and in vivo models to
investigate the genetic influence on the skeletal muscle
cell response to ischemia. Here we demonstrate mouse
strain-dependent differences in the myogenic regulatory
program in response to HLI in vivo and show that these
differences are recapitulated in isolated primary skeletal
muscle cells in vitro. Furthermore, we demonstrate thatthe muscle cell-specific expression of vascular growth
factors and their cognate receptors in vivo and in vitro in
response to ischemia is genetically determined. These
results provide novel insights into the genetic determi-
nants of severe limb ischemia, such as that caused by
CLI, by demonstrating that the same genetic locus linked
to strain-dependent collateral vessel density also has a
nonvascular or muscle cell-autonomous role. These find-
ings establish that muscle–specific responses play a
greater role than previously thought in determining path-
ological outcomes in response to ischemia.
Materials and Methods
Animals
Experiments were conducted on 6- to 8-week-old adult
male C57BL/6 or BALB/c mice (Jackson Laboratory, Bar
Harbor, ME) and were approved by the Duke University
Institutional Animal Care and Use Committee. Surgical
hindlimb ischemia was performed as described previ-
ously.7,9 Briefly, ischemia was induced by anesthetizing
mice by injection of ketamine (90 mg/kg i.p.) and xylazine
(10 mg/kg i.p.), and unilateral hindlimb ischemia was
surgically induced by ligation and excision of the femoral
artery from its origin just above the inguinal ligament to its
bifurcation at the origin of the saphenous and popliteal
arteries. The inferior epigastric, lateral circumflex, and
superficial epigastric artery branches were also isolated
and ligated. Mice were closely monitored during the post-
operative period, and perfusion in the ischemic and con-
tralateral nonischemic limbs was measured immediately
after surgery to verify successful ischemia.
Necrosis Score
The extent of necrosis in ischemic hindlimbs, if any, was
recorded postoperatively using a previously described
semiquantitative scale9: grade 0, no necrosis in ischemic
limb; grade I, necrosis limited to toes; grade II, necrosis
extending to dorsum pedis; grade III, necrosis extending
to crus; and grade IV, necrosis extending to thigh or
complete limb necrosis.
Immunofluorescence Microscopy
Immunofluorescence microscopy was used for visualiza-
tion of muscle morphology, capillary density, apoptosis,
and monocyte infiltration in ischemic and control skeletal
muscle. Transverse sections (8 m thick) were cut from
tibialis anterior (TA) muscle frozen in liquid nitrogen-
cooled isopentane in optimum cutting temperature (OCT)
medium. Sections were allowed to come to room temper-
ature and then were fixed/permeabilized with ice-cold
acetone for 10 minutes at 4°C. Sections were allowed to
air dry for 5 minutes at room temperature and then were
rehydrated in 1 PBS before blocking in 5% normal goat
serum (Sigma-Aldrich, St. Louis, MO) in 1 PBS at room
temperature for 45 minutes. Slides were then incubated
overnight at 4°C in a primary antibody solution containing
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leigh, NC) or mouse IgG2b anti-CD11 (1:100; MAS 034;
Harlan Laboratories, Indianapolis, IN) and mouse IgG2a
anti-dystrophin supernatant (1:5; MANDYS1 3B7; devel-
oped by G.E. Morris and obtained from the Developmen-
tal Studies Hybridoma Bank under the auspices of the
NIH National Institute of Child Health and Human Devel-
opment and maintained by the University of Iowa Depart-
ment of Biology, Iowa City, IA). Slides were then washed
three times in 1 PBS at room temperature and incu-
bated for 1 hour at room temperature in the dark in a
secondary antibody solution containing Alexa Fluor 488-,
568-, or 633-conjugated secondary antibodies in block-
ing solution (all at 1:250 dilution). Sections were then
washed three times for 5 minutes each in the dark with
1 PBS at room temperature. Coverslips were mounted
using Vectashield HardSet mounting medium with DAPI
(H-1500; Vector Laboratories, Burlingame, CA). TUNEL
immunofluorescence staining (Invitrogen; Life Technolo-
gies, Carlsbad, CA) was performed according to the
manufacturer’s recommendations. Images were cap-
tured using a Zeiss Axio Observer inverted laser scan-
ning microscope LSM 510 using Zeiss LSM 510 software
version 4.2 and were analyzed offline using ImageJ soft-
ware version 1.43u (NIH, Bethesda, MD).
Myofiber Cross-Sectional Area
Frozen sections from TA muscle samples were stained
with H&E. Digital images were obtained at 20 magnifi-
cation, and myofiber cross-sectional area (in m2) was
quantified by a single blinded investigator from approxi-
mately 300 myofibers per animal, using NIH ImageJ im-
age analysis software version 1.43u.
Cell Lines and Culture
Immortalized murine C2C12 and rat L6 skeletal muscle
cells were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA). Cells were propagated in
growth medium [Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 1% penicillin/streptomycin
and 0.2% amphotericin B, and 10% fetal bovine serum].
Differentiation was stimulated by serum withdrawal in dif-
ferentiation medium (DMEM supplemented with 2%
horse serum, 1% penicillin/streptomycin, 0.2% amphoter-
icin B, and 0.01% human insulin/transferrin/selenium).
Immortalized EC-RF24 (ECRF) cells (described by Fontijn
et al17) were a gift from Ruud Fontijn and were propa-
gated in DMEM supplemented with 1% penicillin/strepto-
mycin, 0.2% amphotericin B, and 10% fetal bovine se-
rum. Human umbilical vein endothelial cells (HUVECs)
were isolated from donor placental umbilical veins and
were used before passage 6. HUVECs were propagated
on 0.1% gelatin-coated dishes in endothelial basal me-
dium (Lonza, Walkersville, MD) supplemented with 20%
fetal bovine serum, 1% penicillin/streptomycin and 0.2%
amphotericin B, and an EGM-MV bullet kit (Lonza,
Walkersville, MD) containing epidermal growth factor,
bovine brain extract, hydrocortisone, and gentamicin.
To evaluate the effects of ischemia/hypoxia in vitro, weused an established model of cellular hypoxia in which
cells are subjected to 0% O2 and deprived of nutrients
in Hank’s balanced salt solution14 to mimic the local
environment resulting from severe ischemia in PAD,
referred to hereafter as hypoxia plus nutrient depriva-
tion (HND).
Primary Myoblast Isolation and Culture
Primary murine muscle precursor cells (mouse myo-
blasts) derived from diaphragm and hindlimb muscles
were prepared as described previously.18,19 Briefly,
hindlimb and diaphragm muscles were extracted from 4-
to 6-week-old female C57BL/6 or BALB/c mice, digested
with pronase (0.2%) for 60 minutes at 37°C, and then
triturated to release precursor cells. Individual cells were
washed in DMEM and PBS and then preplated for 3 hours
on tissue culture polystyrene dishes; the cellular super-
natant was transferred into collagen-coated (1 mg/mL in
DMEM) plates and maintained in growth medium (Ham’s
F10 medium supplemented with 1% penicillin/streptomy-
cin and 0.2% amphotericin B, 20% fetal bovine serum,
and 2.5 ng/mL hFGF) for 4 days, which allowed myo-
blasts to attach to the substratum and proliferate. Myo-
blasts were then propagated in growth medium and used
in experiments within four passages of isolation. Differ-
entiation was stimulated by serum withdrawal in differen-
tiation medium (DMEM supplemented with 2% horse se-
rum, 1% penicillin/streptomycin, 0.2% amphotericin B,
and 0.01% human insulin/transferrin/selenium) and veri-
fied by light microscopy and quantitative RT-PCR for the
myogenic regulatory factor myogenin. Analysis of the
effects of recombinant VEGF on myoblast differentiation
was performed by plating equal numbers of myoblasts on
plates coated with entactin, collagen, and laminin and
allowing cells to reach 90% confluence. Cells were then
treated with PBS or recombinant human vascular endo-
thelial growth factor (rH-VEGF; 50 ng/mL) in growth me-
dium for 24 hours and analyzed by quantitative RT-PCR.
DNA Fragmentation
DNA fragmentation was analyzed on 1% agarose gels
using 2 g genomic DNA isolated from cells using an
apoptotic-DNA ladder kit (Roche Diagnostics, Indianap-
olis, IN) according to the manufacturer’s instructions.
Myotube Diameter
Muscle myotube diameter was quantified as described
previously.20 Briefly, images of myotubes after treatment
were acquired by phase contrast microscopy at 100
magnification on an Olympus IX70 inverted microscope
connected to a PAXCam ARC digital camera system
(MIS, Franklin Park, IL). Diameters were measured in
100 myotubes from at least 10 random fields (a number
chosen by determining no additional change in standard
deviation) using NIH ImageJ image analysis software
version 1.43u. Each myotube analyzed was measured at
three points along the length of the myotube in a blinded
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control treatment diameter.
Mitochondrial DNA Content
Cellular mitochondrial DNA content was analyzed in total
cellular DNA by quantitative RT-PCR using genomic DNA
isolated from cells using an apoptotic-DNA ladder kit
(Roche Diagnostics) according to the manufacturer’s in-
structions. A primer set against NADH dehydrogenase
subunit 2 (Nd2) was used to quantify the mitochondrial
genome and was corrected for the nuclear-specific gene
Nme1 by quantitative real-time PCR using an ABI 7300
Real-Time PCR System (Applied Biosystems; Life Tech-
nologies, Foster City, CA) as described previously.21
Quantitative RT-PCR
Total RNA was extracted from mouse gastrocnemius
muscles, primary murine skeletal myoblasts, C2C12
murine myoblasts, L6 rat myoblasts, ECRF cells, and
HUVECs using TRIzol (Invitrogen) phenol/chloroform
extraction. RNA (5 g) was reverse-transcribed using
SuperScript III Reverse Transcriptase and random prim-
ers (Invitrogen). Reactions were incubated at 50°C for 50
minutes and at 85°C for 5 minutes. Real-time PCR was
performed using an ABI 7300 system (Applied Biosys-
tems). Relative quantification of GADD45, p21, MyoD,
myogenin, paired box gene (Pax7), Pgc1-, Ang-1,
Ang-2, Tie1, Tie2, VEGF, VEGFR-1/Flt, VEGFR-2/Flk, and
NRP-1 mRNA levels were determined using the compar-
ative threshold cycle (CT) method using FAM TaqMan
gene expression assays (Applied Biosystems) specific
for each of these genes run in complex (multiplex) with a
VIC-labeled GAPDH control primer.
Muscle Cell Hypoxia Response
Strain-specific primary myotube hypoxia responses were
determined in vitro using an adenoviral hypoxia response
element-luciferase reporter construct.22,23 Cells were ad-
enovirally transduced with a hypoxia response element-
luciferase reporter construct and subjected to HND; lu-
ciferin substrate (Promega, Madison, WI) was added and
luciferase activity was measured by bioluminescence im-
aging (IVIS; Xenogen, Hopkinton, MA).
Immunoblotting
Cell cultures or gastrocnemius muscles were washed
twice with ice-cold PBS and lysed on ice in a lysis buffer
consisting of 50 mmol/L HEPES, 150 mmol/L NaCl, 100
mmol/L NaF, 5 mmol/L EDTA, 0.5% Triton X-100, and
protease inhibitors (5 mg/mL aprotinin, 2 mg/mL leupep-
tin, and 100 mmol/L phenylmethylsulfonyl fluoride). Ly-
sates were centrifuged at 1000 g for 5 minutes, and the
supernatant (30 to 80 g total protein) was boiled for 5
minutes in Laemmli sample buffer, and proteins were
separated by SDS-PAGE and analyzed by Western blot-
ting. Antibodies were against phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2, phospho-Akt (Thr308/Ser473), to-
tal Akt, phospho-mTOR (Ser2481), phospho-p70S6K1
(Thr389), total p70S6K1, phospho-FoxO3a (Ser253), Bax,
Bcl-2, and total and cleaved caspase-3 (all purchased
from Cell Signaling Technology, Danvers, MA). Load-
ing and transfer of equal amounts of protein was con-
firmed by Ponceau staining and stripping the mem-
branes and reprobing with antibodies against -tubulin
(for in vitro cell lysate analysis) (Sigma-Aldrich) or
GAPDH (for in vivo gastrocnemius tissue analysis)
(Novus Biologicals, Littleton, CO).
Statistical Analysis
Statistical analysis of within-group differences was per-
formed using one-way analysis of variance; between-
group comparisons were performed using Student’s t-
test. A P value of 0.05 was considered statistically
significant.
Results
Skeletal Muscle Cells, but Not Endothelial Cells,
Display Nuclear and Mitochondrial Damage
after Hypoxia and Nutrient Deprivation
To evaluate the individual responses of different cell
types (endothelial and muscle cells) primarily affected in
the ischemic limb, we used an established in vitro model
of cellular hypoxia in which cells are subjected to hypoxia
Figure 1. Muscle and endothelial cells respond differently to hypoxia and
nutrient deprivation in vitro. Changes in DNA fragmentation (A and B),
mitochondrial DNA content (C and D), and expression of Bax, Bcl-2, and
cleaved caspase-3 (E and F) were assessed in immortalized (mouse C2C12 or
rat L6) or primary BL6 myotubes (A, C, and E) and in immortalized human
ECRF and primary HUVECs (B, D, and F) after 3 hours of hypoxia and
nutrient deprivation (3 hours HND). *P 0.05 versus cell-type control (Con).
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and Hank’s balanced salt solution,14 in an attempt to
reproduce the local O2 and nutrient-depleted environ-
ment resulting from severe ischemia in PAD. Initially, we
examined effects of HND on skeletal myotube and endo-
thelial cell survival. Three hours of HND induced DNA
fragmentation (Figure 1A) in two different immortalized
muscle lines, as well as in primary skeletal myotubes.
DNA fragmentation was not increased in either of two
different types of endothelial cells (Figure 1B). Mitochon-
drial DNA content decreased with HND in all muscle cell
types tested (Figure 1C). Notably, this reduced mitochon-
drial:nuclear DNA ratio was a primary mitochondrial ef-
fect, in that there was a loss of mitochondrial Nd2 without
change in total genomic DNA (nuclear-specific Nme1).
Somewhat surprisingly, mitochondrial DNA content was
either unchanged (immortalized ECRF cells) or increased
significantly (primary HUVECs) in endothelial cells (Fig-
ure 1D). Although this finding is consistent with the lack of
apoptosis, it is opposite that of the skeletal muscle re-
sponse and was due to an increase in copy number of
the mitochondrial gene Nd2. In addition, Western blotting
revealed an increase in the Bax/Bcl-2 protein expression
ratio and caspase-3 cleavage in muscle cells (Figure 1E),
but no change in either measure in endothelial cells (Fig-
ure 1F), further supporting a lack of endothelial cell injury
at this time point. These findings demonstrate that endo-
thelial cells and myotubes display markedly different re-
sponses to the same duration of HND insult, including
different effects on myonuclear apoptosis and mitochon-
drial content.
To further characterize the cachectic signaling re-
sponses of muscle to ischemia such as that occurring in
PAD, mature myotubes were subjected to 3 hours HND
and then were analyzed morphologically. All three mus-
cle cell lines underwent significant atrophy (Figure 2, A
and B). Consistent with this apparent loss of cellular
protein, the phosphorylation of signaling proteins impor-
tant for cell growth and protein synthesis, Akt and p70 S6
kinase, was markedly reduced (Figure 2C). Similarly,
FoxO3a, a critical transcriptional regulator of proteolysisand atrophy in skeletal muscle,24–26 was also dephos-
phorylated, consistent with its activation (Figure 2C). Ac-
cordingly, two ubiquitin ligases involved in atrophic skel-
etal muscle signaling, muscle atrophy F-box protein
(MAFbx, or atrogin-1) and muscle-specific RING finger
protein 1 (MuRF-1),27,28 were transcriptionally up-regu-
lated in response to 3 hours HND in L6 myotubes (Figure
2D). Taken together, these data demonstrate that muscle
cells rapidly undergo atrophy in response to the HND
insult.
Strain-Specific Alterations in the Muscle
Recovery Program Dictate the Pathological
Response to Ischemia in Vivo
Previously published reports have definitively established
the critical influence of genetics on the differential re-
sponses to HLI in C57BL/6 (BL6) and BALB/c mice in
vivo.8–10 Specifically, perfusion recovers almost com-
pletely in BL6 mice, whereas BALB/c mice suffer severe
limb necrosis. To expand on these findings and to extend
our in vitro results in myocytes and endothelial cells, we
examined whether strain-specific differences in the limb
muscle response to ischemia suggest a myocyte-specific
deficit. BALB/c mice responded to ischemia with signifi-
cantly greater semiquantitative necrosis scores (Figure
3A), although capillary density (Figure 3B) was not sig-
nificantly different in the two strains at baseline or after 7
days of HLI. Differential patterns of TUNEL staining were
observed, with rampant nuclear apoptosis 1 day after HLI
in both strains that decreased by day 7 in BL6 but not in
BALB/c muscle (Figure 3C). Notably, entire BALB/c myo-
fibers frequently stained TUNEL, an effect not observed
at any time point in the BL6 muscle. Immunofluorescence
staining for monocytes revealed inflammatory cell infiltra-
tion in both strains, peaking at day 3 and subsequently
declining by day 7 after HLI only in the BL6 muscle
(Figure 3D). Immunofluorescence and H&E staining also
revealed striking strain-dependent morphological differ-
ences during the initial week of recovery.
Figure 2. The myotube response to hypoxia and
nutrient deprivation in vitro includes atrophic sig-
naling pathways. Immortalized mouse C2C12 and
rat L6 and primary BL6 myotubes were induced to
differentiate, subjected to 3 hours HND, and ana-
lyzed for traditional protein synthetic and degrada-
tive responses. A: Representative images of differ-
entiated C2C12 myotubes before (Con) and after 3
hours HND. B: Myotube diameter was quantified
in each cell type before (Con) and after 3 hours
HND. C: Cell lysates from control (Con) and
3-hour HND-treated myotubes were assessed by
Western blot for proteins involved in synthetic
(pAkt, p-p70S6K) and degradative (pFoxO3a) sig-
naling; -tubulin was used as a loading control. D:
Changes in mRNA expression of the muscle-spe-
cific ubiquitin ligases MAFbx and MuRF-1 were
quantified in C2C12 myotubes after control or
3-hour HND treatment. *P  0.05 versus cell-type
control.
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regeneration, with restoration of immunoreactive dystro-
phin staining and abundant centralized myonuclei (Fig-
ure 4A). In contrast, BALB/c muscle displayed continued
loss of dystrophin immunoreactivity and lack of morpho-
logical indices of muscle regeneration. Although signifi-
cant muscle atrophy, measured by changes in gastroc-
nemius muscle wet weight, was observed in both strains
on day 7 after HLI, BALB/c muscle displayed a significant
increase in weight at day 3, consistent with increased
edema, followed by atrophy and necrosis (Figure 4B).
Although gastrocnemius muscle fiber diameters were not
significantly different between BALB/c and BL6 mice at
baseline or at 7 days after HLI (Figure 4C), the number of
myofibers with centralized nuclei, a histological marker of
ongoing muscle regeneration, was markedly attenuated
at day 7 of HLI in BALB/c mouse muscle (Figure 4D).
Western blotting of gastrocnemius muscle lysates dur-
ing the initial week of HLI revealed decreases (days 1
Figure 3. BL6 and BALB/c mice display differential strain-dependent re-
sponses to ischemia in vivo. BL6 and BALB/c mice were subjected to
hindlimb ischemia (HLI) or sham surgery (n  3 per group) and allowed to
recover for 1, 3, or 7 days. A: Limbs were analyzed for necrosis score at the
three time points. NR, none recorded. B: Capillary density was assessed by
CD31 staining of TA muscle and quantified as capillaries per fiber. C: Rep-
resentative images of TA muscle from mice at 1-, 3-, and 7-day recovery times
stained for dystrophin (myofibers, red), TUNEL (apoptosis, green), and DAPI
(nuclei, blue). D: Representative images from TA muscle costained for dys-
trophin (red) and CD11b (monocytes, green). In C and D, note the greater
and persistent apoptosis and monocyte infiltration. *P  0.05 versus strain-
specific control (Sham). Original magnification: 200 (C and D).and 3) and subsequent recovery or increases (day 7) inthe phosphorylation of protein synthetic signaling com-
ponents (Akt, mTOR, p70 S6 kinase) in BL6 mice (Figure
5A). Similarly, dephosphorylation of FoxO3a, dephos-
phorylation of p42/44 MAPK, and a relative increase in
the Bax/Bcl-2 protein ratio all occurred between days 1
and 3 but were rescued by day 7 of HLI in BL6 mice.
BALB/c mice, however, demonstrated similar changes in
each of these markers early, but failed to show recovery
by day 7 (Figure 5A).
Last of all, we analyzed the genetic program of muscle
precursor cell differentiation and maturation in gastroc-
nemius muscle from both strains of mice after HLI (Figure
5B). Increases in mRNA expression of the cell cycle
withdrawal factors GADD45 and p21 as well as the myo-
genic regulatory factors MyoD and myogenin were sig-
nificantly attenuated in BALB/c mice in the initial week of
HLI. Similarly, expression of myostatin, the ubiquitin li-
gases MAFbx and MuRF-1, and Pgc1- was significantly
suppressed in BALB/c mice during the initial week of HLI
(Figure 5C). These gene expression data suggest that
the normal atrophic and myogenic transcriptional pro-
grams activated by ischemia in BL6 mice are disrupted in
BALB/c mice, potentially contributing to overall limb ne-
crosis. Collectively, these results demonstrate an orga-
nized recovery of skeletal muscle after HLI in BL6 mice
that is lacking in BALB/c mice, because of genetic vari-
ability.
Strain-Specific Alterations in Muscle Precursor
Cell Activation Regulate the Ischemic Response
Our earlier in vitro data demonstrated that HND has a
greater effect on muscle cells than on endothelial cells,
suggesting that the inability of BALB/c mice to mount an
effective survival and/or recovery response to HLI may be
due to a deficit in muscle precursor cell activation. To
investigate the strain-specific effects of ischemia/hypoxia
on skeletal muscle precursor cells, we isolated primary
satellite cells from both BL6 and BALB/c mice and sub-
jected them to HND in vitro, subsequently allowing cells
from both strains to recover under identical oxygenation
and nutritional conditions. In this manner, we effectively
eliminated any contribution of the vasculature to the mus-
cle precursor cell regeneration or differentiation program.
The overall capacity to mount a hypoxia response, as
evidenced using a hypoxia response element-luciferase
reporter, was similar for primary muscle cells from both
strains (data not shown). Morphologically, primary myo-
blasts and myotubes from BL6 and BALB/c mice looked
similar and differentiated similarly (Figure 6A). Myotubes
from both strains displayed a similar degree of atrophy
after 3 hours HND, but BALB/c precursor cells failed to
recover over 5 days (Figure 6, A and B). This morpho-
logical defect was accompanied by attenuated expres-
sion of the anti-apoptotic protein Bcl-2 (Figure 6C), as
well as blunted phosphorylation of Akt and p70 S6 kinase
and sustained dephosphorylation of FoxO3a (Figure 6D).
The genetic program of precursor cell activation and
differentiation during recovery from HND revealed simi-
larities in the expression patterns of the cyclin D1,
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ing no differences in satellite cell proliferative capacity.
However, significant deficits were observed in BALB/c
muscle cells in the expression of the activity marker
PAX7 and the muscle-specific myogenic regulatory
factors MyoD and myogenin (Figure 6F). Expression of
the hypoxia-responsive atrophic gene myostatin in-
creased early in BALB/c myotubes, and the patterns of
MAFbx and MuRF-1 induction remained similar to those
of BL6 during recovery (Figure 6F). Together, these data
demonstrate that BALB/c muscle precursor cells ex-
hibit significant defects in the activation/regeneration
program necessary for recovery from hypoxia and nu-
trient deprivation.
To investigate whether the observed differences in the
satellite cell response to ischemia are due to the previ-
ously identified chromosome 7 QTL, we used primary
myoblasts isolated from congenic BALB/c mice in which
the 37-gene Lsq-1 QTL was selectively replaced with the
same locus from BL6 mice (BALB/cBL6 QTL7).9 Primary
myoblasts and myotubes from these mice appeared mor-
phologically similar to those of the other two strains anddifferentiated normally (data not shown). HND-induced
atrophy of BALB/cBL6 QTL7 myotubes was similar to that of
both parental strains after 3 hours; however, unlike
BALB/c primary cells, these cells recovered fully over 5
days, like the BL6 myocytes (Figure 6E). These findings
confirm that genes within the Lsq-1 QTL are responsible
for the muscle cell-specific response to ischemia.
Muscle Precursor Cells Display Strain-Specific
Differences in Expression of Vascular Growth
Factors and their Receptors
Crosstalk between muscle precursor cells and the vas-
culature plays an important role in the recovery of muscle
tissue from ischemia. Satellite cells, which reside in close
proximity to myofiber capillaries, receive support from
endothelial cells in the form of growth factors (bFGF,
IGF-1, HGF, VEGF, and PDGF-BB). In return, satellite
cells express VEGF to stimulate neovascularization.29,30
Although evidence shows that receptors expressed pre-
Figure 4. BL6 and BALB/c myofibers differen-
tially recover from ischemia in vivo. BL6 and
BALB/c mice were subjected to hindlimb ischemia
(HLI) or sham surgery (n  3 per group) and
allowed to recover for 7 days. A: Representative
images from TA muscle stained for dystrophin
(myofibers, red) and DAPI (nuclei, blue) or H&E
for morphology. Note the attenuated myofiber re-
covery in BALB/c versus BL6. B: Gastrocnemius
muscle tissue was removed at 1, 3, or 7 days after
HLI and analyzed for wet weight. C: Mean myo-
fiber cross-sectional area (CSA)was assessed in nonis-
chemic (Sham) gastrocnemius muscle and 7 days after
HLI. D: Percentage of TA muscle fibers with central-
ized nuclei was assessed 7 days after HLI. *P  0.05
versus strain-specific control (Sham). Original mag-
nification: 200 (A, left column); 300 (A, right
column).dominantly on endothelial cells (Tie and VEGF receptors)
pecific
train-spe
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clear whether these receptors and their ligands (angio-
poietins and VEGF) play a role in determining the survival
and recovery of myofibers after ischemia. We first inves-
tigated the strain-specific differences in ischemic muscle
expression of vascular growth factors and their receptors
in vivo. Analysis of gastrocnemius tissue from BL6 and
BALB/c mice revealed similar patterns of expression of
angiopoietins 1 and 2 (Ang-1 and Ang-2) and their re-
ceptor tyrosine kinases Tie1 and Tie2 (Figure 7, A, C, E,
and G). Under ischemic conditions, limb muscle expres-
sion of the Ang-1 ligand and both Tie1 and Tie2 receptors
decreased, whereas Ang-2 mRNA was significantly in-
creased on day 1 of HLI. Because this analysis reflects
expression from both muscle and nonmuscle cells, we
next investigated expression of these factors in primary
myoblasts from both BL6 and BALB/c mice subjected to
HND. Notably, in vitro analysis revealed similar patterns of
expression of Ang-1 (Figure 7B) and Tie2 (Figure 7H) for
both strains, but significantly different expression pat-
terns of Ang-2 (Figure 7D) and Tie1 mRNA (Figure 7F)
during recovery from HND. These findings revealed a
specific Ang-2/Tie1 ligand/receptor alteration in BALB/c
precursor cells that was masked by in vivo analysis of
Figure 5. The strain-dependent limb tissue response to ischemia in vivo alt
or sham surgery and allowed to recover for 1, 3, or 7 days. A: Gastrocnemius
and degradation, proliferation (p42/44 ERK), and apoptosis (Bax/Bcl-2). B: G
of the muscle cell cycle regulatory genes (GADD45, p21, MyoD, myogenin) w
by quantitative RT-PCR for fold changes in mRNA for myostatin, the muscle-s
*P  0.05 versus strain-specific control (Sham); †P  0.05 versus all other swhole limb muscle.VEGF plays a critical role in skeletal muscle angiogen-
esis and vascular survival and has been shown to regu-
late myoblast proliferation.31,33,34 Therefore, we next in-
vestigated the strain-specific differences in VEGF
expression in response to ischemia in vivo and HND in
vitro. We subjected both HUVECs (Figure 8A) and differ-
entiated C2C12 myotubes (Figure 8B) to sustained HND
for 3, 8, or 24 hours and analyzed VEGF mRNA expres-
sion using quantitative RT-PCR. VEGF mRNA increased
with all durations of HND in both HUVECs and C2C12
cells, although the degree of up-regulation was markedly
greater (40-fold) after 24 hours HND in C2C12 myo-
tubes. Analysis of gastrocnemius muscle revealed sig-
nificantly greater baseline VEGF mRNA expression in
BALB/c mice, but no induction during the week of
recovery from HLI, in contrast to a significant increase
on day 1 in BL6 muscle (Figure 8C). In vitro analysis of
muscle precursor cell-specific expression revealed no
difference between strains in VEGF expression during
recovery from HND (Figure 8D), suggesting that the
differences observed in vivo might be attributable to
other cell types, such as endothelial cells and inflam-
matory cells.
To use VEGF ligand, cells must express sufficient lev-
myogenic regulatory program. BL6 and BALB/c mice were subjected to HLI
homogenates were assessed by Western blot for markers of protein synthesis
emius muscle RNA was harvested and the fold change in mRNA expression
rmined by quantitative RT-PCR. C: Samples shown in panel B were analyzed
ubiquitin ligases (MAFbx and MuRF-1), and the metabolic regulator PGC1-.
cific time points; ‡P  0.05 versus BL6 control (Sham).ers the
muscle
astrocn
as deteels of VEGF receptors. In vivo analysis of gastrocnemius
ne cell c
s BL6 c
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VEGFR-2 and NRP-1 in BALB/c muscle, but similar pat-
terns of expression of VEGFR-1 (Figure 9A), VEGFR-2
(Figure 9C), and NRP-1 (Figure 9E) in BL6 and BALB/c
mice after HLI. In analysis of primary muscle precursor
cells in vitro, myoblasts from BL6 mice demonstrated
significantly increased expression of VEGFR-1 (Figure
9B), VEGFR-2 (Figure 9D), and NRP-1 (Figure 9F) during
recovery from HND. In stark contrast, BALB/c myoblast
expression of all three VEGF receptors was not only sig-
nificantly lower at baseline but also never increased dur-
ing recovery, suggesting a strain-specific deficit in the
ability of satellite cells to respond to VEGF ligand-in-
duced signaling during recovery from ischemia.
To investigate the potential biological relevance of this
deficit in VEGF receptor expression, we examined the
effects of VEGF on skeletal myoblast differentiation, as
would occur during satellite cell activation in response to
muscle injury. Confluent myoblasts were treated with PBS
or recombinant VEGF for 24 hours in normal growth me-
dium. VEGF decreased expression of the cell cycle reg-
ulator cyclin D1 (Figure 10A) and significantly increased
expression of the cell cycle withdrawal factor p21 (Figure
10B) and the myogenic regulatory factors MyoD (Figure
10C) and myogenin (Figure 10D). These findings dem-
onstrate that VEGF induces a gene expression pattern
Figure 6. Primary skeletal muscle cells display strain-dependent differences
BL6 and BALB/c mice, induced to differentiate, then subjected to 3 hours H
cultured skeletal myotubes subjected to 3 hours HND and 72 hours recover
C and D: Primary myotube lysates were Western blotted with antibodies to
and recovery. E: Diameters of primary myotubes from congenic BALB/cBL6
for quantitative RT-PCR to quantify fold changes in mRNA abundance of ni
(Con). †P  0.05 versus all other strain-specific time points; ‡P  0.05 versuconsistent with myoblast differentiation under these con-ditions, and they also support the possibility that deficits
in myoblast VEGF receptor expression could contribute
to the impaired response to ischemia in BALB/c mice.
Discussion
It has become increasingly apparent that the overall de-
gree of tissue damage in response to ischemia is mech-
anistically linked to individual genetic differences, and
there is a critical need to identify the factors that regulate
this response.9,12 With the present study, we have dem-
onstrated that the responses of skeletal muscle cells play
a major role in tissue survival after ischemia. In particular,
genetic differences in affected skeletal muscle cells may
be a major factor determining the severity of disease in
PAD. Our findings demonstrate that the transcriptional
program of myogenic precursor cell activation is retarded
in a strain-dependent manner after tissue ischemia in vivo
and HND in vitro. These findings shed important light on
the individual cellular responses to ischemia and suggest
that myocytes themselves may in fact represent an effec-
tive target for therapeutic intervention in patients with CLI.
Furthermore, we expanded on these observations by
demonstrating that skeletal muscle cells are capable not
only of inducing an angiogenic transcriptional program
yogenic regulatory program in vitro. Primary myoblasts were isolated from
allowed to recover for various lengths of time. A: Representative images of
in normal O2 and nutrients. B: Primary myotube diameters were quantified.
anges in apoptosis (C) and regulators of protein synthesis (D) during HND
e were quantified. F: RNA was harvested from primary myotubes and used
ycle or myogenic regulatory genes. *P  0.05 versus strain-specific control
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factors in an autocrine manner via the expression of Tie
and VEGF receptors. Although we observed few strain-
dependent differences in angiogenic growth factor ex-
pression, differences in Tie1 and VEGF receptor expres-
sion were significant, suggesting that the autocrine
responses of muscle cells to angiogenic signals may play
an important role in the tissue response to ischemia.
Taken together, our results suggest that the genetic sus-
ceptibility of skeletal muscle to ischemia may be medi-
ated largely by the responses of skeletal myofibers and
satellite cells.
In PAD, perfusion is insufficient to meet the metabolic
demands of the tissue and so PAD frequently results in
skeletal myopathy and mitochondrial dysfunction.35,36
The degree of muscle survival or necrosis determines the
ultimate clinical manifestation of PAD, although previous
studies have demonstrated that pre-existing collateral
vessels are critical determinants of the response to isch-
emia and that these collateral vessels are also genetically
Figure 7. Skeletal muscle cells exhibit strain-dependent differences in an-
giopoietin ligand and Tie receptor gene expression. RNA was harvested from
gastrocnemius muscle in vivo (A, C, E, and G) and primary myotubes in vitro
(B, D, F, and H) from BL6 and BALB/c mice, and the fold change in mRNA
expression was determined by quantitative RT-PCR for Ang-1, Ang-2, Tie1,
and Tie2. In all cases, BL6 Sham and BL6 control (Con) were normalized to
1.0. *P  0.05 versus cell- or strain-specific control. †P  0.05 versus all other
strain-specific time points; ‡P  0.05 versus BL6 control (Sham).determined.10–12,37 Our data do not rule out the possibil-ity of pre-existing or nascent collateral vessels as key
players in the ischemic response. However, using a well-
controlled in vitro model of hypoxia and nutrient depriva-
tion in which collateral blood vessels are absent, we
found that myotubes are more susceptible than endothe-
lial cells to the ischemic/hypoxic insult. The rapid re-
sponse of skeletal muscle cells in this model represented
a shift toward cellular catabolism and apoptosis, which
could be reversed with restoration of normal culture con-
ditions. This response, coupled with the relative tolerance
of endothelial cells, suggests that in vivo skeletal muscle
is programmed to preserve vascular integrity and to sac-
rifice myofiber homeostasis during ischemia. Accord-
ingly, apoptosis was more pronounced in muscle than in
endothelial cells in the present study. Given the unique
ability of muscle to regenerate, our findings lend cre-
dence to the idea of evolutionary selection for muscle
plasticity as a protective mechanism in ischemia until
blood flow can be restored by collateral vessel formation
or angiogenesis. Although it is unclear whether the
BALB/c genotype confers any particular selection advan-
tage in muscle (eg, differences in baseline metabolic
function or efficiency), it is possible that similar polymor-
phisms contribute to human CLI.
Previous work by our group9,12 and by others10,11,38
has demonstrated differential vascular responses in
C57BL/6 and BALB/c mouse strains in response to limb
or cerebral ischemia. In our earlier study linking tissue
necrosis and perfusion recovery after HLI to Lsq-1 on
chromosome 7,9 it was somewhat surprising to find that
none of the 37 genes implicated by haplotype analysis
within this QTL had a previously described function in
angiogenesis (eg, encoding angiogenic growth factors
Figure 8. Cell type- and strain-dependent differences in VEGF expression. A
and B: HUVECs (A) and C2C12 myotubes (B) were subjected to HND for 3,
8 or 24 hours and the fold change in VEGF mRNA was determined by
quantitative RT-PCR. C and D: RNA was harvested from gastrocnemius
muscle (C) or primary myotubes (D) from BL6 and BALB/c mice. Fold
change in VEGF mRNA was determined by quantitative RT-PCR. *P  0.05
†versus cell- or strain-specific control (Con). P  0.05 versus all other strain-
specific time points; ‡P  0.05 versus BL6 control (Sham).
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ucts have well-defined roles in the immune response (integ-
rin M/CD11b), tissue remodeling (MMP21, ADAM12), or
metabolism (cytochrome c oxidase), which could be in-
volved in arteriogenesis, angiogenesis, or cellular sur-
vival. Baseline collateral vessel number in hindlimb and
brain has been shown to be strain-dependent,11,38–40
and the genetic locus (Canq-1) linked to collateral phe-
notype maps to the same position as Lsq-1,11 which has
been linked to tissue survival after hindlimb and cerebral
ischemia.9,12
It is important to note that genetically determined dif-
ferences in collateral vessel density likely contribute to
tissue protection from ischemia. Because we focused on
the initial 7-day response, it is possible that we caught a
glimpse into the biology of the ischemic response before
the onset of any changes in vascularity (either capillary
regression or angiogenesis). Blood flow to the ischemic
limb recovers almost completely over 21 days only in the
BL6 strain, although both strains recover a large percent-
age of their perfusion deficit in the initial week of HLI.9 In
the context of the present study, this may suggest that
pre-existing collateral vessels and capillaries may deter-
mine flow to the tissue in the initial week, but that longer
periods of ischemic injury might result in capillary regres-
sion and collateral vessel failure in BALB/c mice, in part
due to extensive tissue necrosis, whereas BL6 mice
might mount an angiogenic response. Nonetheless, our
present observations in isolated muscle cells in vitro, in-
Figure 9. Skeletal muscle cells exhibit strain-dependent differences in VEGF
receptor gene expression. RNA was harvested from gastrocnemius muscle
(A, C, and E) or primary myotubes (B, D, and F) from BL6 and BALB/c mice.
Fold change in VEGF receptor mRNA was determined by quantitative RT-
PCR. *P  0.05 versus cell- or strain-specific control (Con). †P  0.05 versus
all other strain-specific time points; ‡P  0.05 versus BL6 control (Sham).cluding cells from BALB/cBL6 QTL7 mice, indicate that thislocus plays an important role in the plasticity and survival
of muscle precursor cells and myotubes, independent of
the vascular contribution to the ischemic response. Al-
though it is possible that collateral vessel density and the
muscle response to ischemia are genetically coregu-
lated, our data suggest that effects on nonvascular cells
may be equally important or more important than effects
on angiogenesis in determining the ultimate outcome of
ischemia.
Strain-specific differences in the regeneration capacity
of muscle have generally been overlooked. After intra-
muscular toxin injection, BALB/c mice displayed pro-
nounced collagen deposition and blunted myofiber re-
generation, findings that were not observed in BL6
mice.41 Separate studies also demonstrated a BALB/c
strain-specific deficit in muscle regeneration after crush
injury or isografting.42–46 A common hypothesis for this
strain-dependent defect is that type 2 cytokine produc-
tion (high IL-4) in BALB/c mice results in differential mac-
rophage activity and delayed tissue phagocytosis and
satellite cell activation.41 The local environment likely also
plays a critical role, with significant deficits observed in
muscle precursor cell DNA synthesis, leukocyte infiltra-
tion, and myotube formation when BALB/c mice are used
as transplantation recipients.46 BALB/c-specific delays in
satellite cell activation after crush injury have been re-
ported,43,44 although it was subsequently determined
that differences in bone marrow-derived inflammatory
cells could not account for these findings.45 Our in vivo
data demonstrate that macrophage infiltration proceeds
along a similar timeline regardless of mouse strain, al-
though inflammation persists longer in BALB/c muscle.
Our in vitro data in primary myoblasts further support the
idea that monocytes are not the primary cause of the
Figure 10. Exogenous VEGF enhances myoblast differentiation. Primary
mouse myoblasts were grown to confluence and treated with PBS or recom-
binant human vascular endothelial growth factor (rH-VEGF; 50 ng/mL) in
growth medium for 24 hours, and RNA was harvested and analyzed by
quantitative RT-PCR for expression of cyclin D1 (A), p21 (B), MyoD (C), and
myogenin (D). *P  0.05 versus PBS-treated myoblasts.
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the muscle cells themselves is a critical determinant of
the myoblast differentiation program and resistance to
hypoxia.
Although the transcriptional response to hypoxia is
classically linked to stabilization of hypoxia-inducible fac-
tor 1- (HIF-1-),47 recent evidence has shown that VEGF
expression and angiogenesis in limb ischemia are
HIF-independent and peroxisome proliferator-activated
receptor gamma coactivator (PGC) 1-–dependent.14
Although this finding may be related to differential re-
sponses of endothelial and skeletal muscle cells, our
results suggest a common program of angiopoietin and
Tie receptor gene expression in limb muscle during the
initial week of ischemia, independent of mouse strain.
Whereas our results are consistent with previous studies
demonstrating expression of the Tie receptors in myo-
blasts in vitro,32 we observed a distinct expression pat-
tern in BALB/c mice in which Ang-2 was significantly
enhanced but Tie1 expression was suppressed during
recovery from HND. Although Tie1 signaling has not been
well studied,48 several reports have linked Ang-2 and
Tie1 to common functions, including inflammation49,50
and lymphangiogenesis,51–53 and recent structural evi-
dence demonstrates differences in the interaction of
Ang-2 with Tie1 versus Tie2.54 Although the exact role of
this strain-dependent differential Ang-2/Tie1 expression
in muscle cells is not yet known, it may be responsible for
differences in angiogenesis, inflammation, and/or myo-
blast survival or differentiation and therefore may be part
of the genetically determined response to limb ischemia.
We observed a significant attenuation in limb muscle
expression of VEGF at 1 day after HLI in BALB/c mice,
although this deficit did not persist at later stages of
recovery. Moreover, this in vivo difference did not trans-
late into a strain-dependent difference in muscle cell
VEGF mRNA expression in vitro, suggesting that the mus-
cle precursor cell contribution to VEGF expression may
not be a significant factor in the limb muscle response.
However, there were striking differences in myotube ex-
pression of VEGF receptors in vitro after HND, which were
significantly up-regulated in BL6 but not BALB/c myo-
cytes. This effect was not observed in vivo after HLI, but
could have been masked by the vascular response to
ischemia. This muscle-specific change in VEGF receptor
expression suggests an ability of muscle cells to respond
to VEGF during recovery from ischemia and suggests
that a growth factor traditionally linked to endothelial cell
activation may serve a dual purpose by also promoting
satellite cell and/or myofiber survival and recovery. Al-
though relatively little is known about the biological role of
VEGF receptors in muscle cells, this possibility is consis-
tent with several previous reports demonstrating re-
sponses of myoblasts to VEGF and expression of VEGF
receptors in muscle cells during ischemia.15,31,55 In ad-
dition, muscle-derived stem cells expressing VEGFR-2
have been shown to contribute to skeletal muscle regen-
eration,56 and expression of VEGF and VEGFR-2 have
been localized to atrophic and regenerating muscle cells
in ischemic muscle.57 In support of previous data dem-
onstrating a biological role for VEGF in myoblast differ-entiation,58 our in vitro data on the promotion of the ge-
netic myoblast differentiation program by exogenous
VEGF strongly suggest that genetic differences in poten-
tial responsiveness to growth factors traditionally charac-
terized as exclusively angiogenic, such as VEGF and the
angiopoietins, may contribute to the ability of skeletal
muscle to withstand and recover from ischemia.
In conclusion, our data demonstrate an important
and previously unrecognized genetic component to
the skeletal muscle–specific response to ischemia in
mice. In humans, similar genetic regulatory mecha-
nisms may contribute to a patient’s predisposition to
develop CLI. Whereas our data suggest that endothe-
lial cells are more ischemia-tolerant than muscle cells,
our results did not address a genetic contribution to the
effects of hypoxia or ischemia on endothelial cell sur-
vival or angiogenesis. Nonetheless, our observation of
strain-dependent differences in muscle cell–specific
expression of vascular growth factors and their recep-
tors demonstrates that genetic differences in these
cells can extend to the vascular response. Moreover,
these findings suggest that, in addition to promoting
vascular remodeling through the paracrine secretion of
vascular growth factors like VEGF, muscle cells can
potentially respond to these same factors in an auto-
crine fashion under conditions of stress or injury. Taken
together, these results suggest that identifying genetic
determinants of the skeletal muscle cell response to
ischemia may lead to new targets for the treatment of
patients with CLI.
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